A Large Population Histology Study Showing the Lack of Association between ALT Elevation and Significant Fibrosis in Chronic Hepatitis B by Seto, Wai-Kay et al.
A Large Population Histology Study Showing the Lack of
Association between ALT Elevation and Significant
Fibrosis in Chronic Hepatitis B
Wai-Kay Seto
1, Ching-Lung Lai
1,3, Philip P. C. Ip
2, James Fung
1, Danny Ka-Ho Wong
1, John Chi-Hang
Yuen
1, Ivan Fan-Ngai Hung
1, Man-Fung Yuen
1,3*
1Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, 2Department of Pathology, The University of Hong Kong, Queen Mary
Hospital, Hong Kong, 3State Key Laboratory for Liver Research, The University of Hong Kong, Queen Mary Hospital, Hong Kong
Abstract
Objective: We determined the association between various clinical parameters and significant liver injury in both hepatitis B
e antigen (HBeAg)-positive and HBeAg-negative patients.
Methods: From 1994 to 2008, liver biopsy was performed on 319 treatment-naı ¨ve CHB patients. Histologic assessment was
based on the Knodell histologic activity index for necroinflammation and the Ishak fibrosis staging for fibrosis.
Results: 211 HBeAg-positive and 108 HBeAg-negative patients were recruited, with a median age of 31 and 46 years
respectively. 9 out of 40 (22.5%) HBeAg-positive patients with normal ALT had significant histologic abnormalities
(necroinflammation grading $7 or fibrosis score $3). There was a significant difference in fibrosis scores among HBeAg-
positive patients with an ALT level within the Prati criteria (30 U/L for men, 19 U/L for women) and patients with a normal
ALT but exceeding the Prati criteria (p=0.024). Age, aspartate aminotransferase and platelet count were independent
predictors of significant fibrosis in HBeAg-positive patients with an elevated ALT by multivariate analysis (p=0.007, 0.047
and 0.045 respectively). HBV DNA and platelet count were predictors of significant fibrosis in HBeAg-negative disease
(p=0.020 and 0.015 respectively). An elevated ALT was not predictive of significant fibrosis for HBeAg-positive (p=0.345)
and -negative (p=0.544) disease. There was no significant difference in fibrosis staging among ALT 1–26upper limit of
normal (ULN) and .62 ULN for both HBeAg-positive (p=0.098) and -negative (p=0.838) disease.
Conclusion: An elevated ALT does not accurately predict significant liver injury. Decisions on commencing antiviral therapy
should not be heavily based on a particular ALT threshold.
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Introduction
Clinical course of chronic hepatitis B (CHB) is highly variable,
ranging from an asymptomatic carrier state [1,2] to the
development of cirrhosis, hepatic decompensation and hepatocel-
lular carcinoma (HCC) [3]. The aim of CHB treatment is to
prevent the development of these long-term complications, of
which effective implementation would require identification of
high-risk patients. Histologic injury and fibrosis have a good
correlation with long-term risk, since repeated hepatitic flares in
CHB were found to have increased necroinflammation on liver
biopsies, resulting in increased fibrogenesis and eventual disease
progression [4].
Serum alanine aminotransferase (ALT) is an important
biochemical marker used in the assessment of hepatic injury, but
is limited by its poor correlation with disease severity [5]. Serum
HBV DNA levels directly reflect the degree of HBV replication,
and are strongly correlated with long-term mortality [6,7].
However, patients in the immune tolerant phase have minimal
changes on liver biopsy despite high HBV DNA levels [8].
Although liver biopsy remains an integral part in determining
disease severity , it is an invasive procedure and not without
complications [9]. Sampling error and intra-observer variations
are also unavoidable [10,11].
Current treatment guidelines recommend the use of both serum
ALT and HBV DNA in selecting patients for therapy, with a
persistent ALT level of more than 26upper limit of normal (ULN)
required for commencing therapy in two of the three international
treatment guidelines on CHB [12,13]. Certain subgroups still
require consideration of liver biopsy. These include hepatitis B e
antigen (HBeAg)-positive patients of 40 years and older with ALT
1–26ULN, and HBeAg-negative patients with ALT 1–26ULN
and an elevated HBV DNA (more than 1610
4 copies/mL or
2000 IU/mL). A study of 4376 HBeAg-negative patients from
Taiwan claimed that normal ALT levels in HBeAg-negative
disease had good prognosis [14]. However, other studies have
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already having significant necroinflammation, fibrosis and even
cirrhosis on liver biopsy [10,15,16]. An Italian population study by
Prati et al based on 6835 healthy individuals suggested to lower the
ULN of ALT to 30 U/L for men and 19 U/L for women [17],
making the definition of ‘‘normal ALT’’ more confusing.
Previous studies investigating the association between clinical
parameters and advanced histologic abnormalities were limited by
either a small sample size or a disproportional distribution of
HBeAg-positive and -negative disease [18,19,20,21]. The present
study aimed at studying the association between ALT and
advanced histologic abnormalities in the 3 phases of HBV
replication: the immune tolerant phase, the immune clearance
phase and HBeAg-negative disease.
Methods
From 1994 to 2008, 1054 treatment-naive CHB patients
followed up in the Department of Medicine, the University of
Hong Kong, Queen Mary Hospital were screened for entry into
therapeutic drug trials that required liver biopsy. Three hundred
and nineteen out of these 1054 patients with similar demographics
and clinical characteristics who had consented to enter these trials
were recruited in the present study. In addition, we had previously
investigated and reported the usage of routinely available clinical
parameters to derive a score to predict significant fibrosis in CHB
based on 237 out of these 319 patientss [22].
Patients were recruited if they were positive for hepatitis B
surface antigen (HBsAg) for at least 6 months and had available
baseline biochemical and hematological parameters on presenta-
tion. The inclusion criteria for ALT and HBV DNA for each
therapeutic drug trial differed, and are listed in Table 1. Patients
who had decompensated liver disease and other concomitant liver
disease, including chronic hepatitis C or D virus infection, primary
biliary cirrhosis, autoimmune hepatitis, Wilson’s disease, and
significant intake of alcohol (20 grams per day for female; 30
grams per day for male) were excluded. All patients had written
consent on entry into trials for research purposes, and all trials
were approved by the Institutional Review Board of the University
of Hong Kong.
Clinical and biochemical parameters were recorded from all
patients at the day of liver biopsy. These include the patient’s age,
gender, HBeAg status, albumin, bilirubin, ALT, AST, platelet
count and HBV DNA level. The ULN of ALT was based on the
respective therapeutic drug trials, and was ranged from 45 to
53 U/L in men and 31 to 43 U/L in women. Serum HBV DNA
levels were measured by three different assays, as follow: a
branched DNA assay (Versant HBV DNA 3.0 assay, Bayer
Health-Care Diagnostic Division, Tarrytown, NY), with a lower
limit of quantification of 2000 copies/mL (400 IU/mL) in 88
patients, Cobas Amplicor HBV Monitor Test (Roche Diagnostic,
Branchburg, NJ) with a lower limit of quantification of 300 copies/
mL (60 IU/mL) in 115 patients, Cobas Taqman assay (Roche
Diagnostic, Branchburg, NJ) with a lower limit of quantification of
60 copies/mL (12 IU/mL) in 116 patients.
Two different biopsy needles were used to obtain liver biopsies.
An 18G sheathed cutting needle (Temno Evolution, Cardinal
Health, McGaw Park, IL) was used for 88 patients, of which the
biopsies obtained were 1.5 to 1.8 cm in length. For the rest of the
cohort, liver biopsies were obtained using a 17G core aspiration
needle (Hepafix, B. Braun Melsungen AG, Germany), with a
biopsy length between 2 to 5 cm. Only pre-treatment biopsies
were included. Biopsies were fixed, paraffin-embedded, and
stained with hematoxylin and eosin for morphological evaluation
and Masson’s trichrome stain for assessment of fibrosis. The
pathologist assessing the biopsy specimens was blinded to the
biochemical and virologic results of the patients. Histologic
grading of necroinflammation and the staging of liver fibrosis
were performed using the Knodell histologic activity index (HAI)
[23] and Ishak fibrosis score [24] respectively. Necroinflammation
was graded from 0 to 18 while fibrosis was staged from 0 to 6.
Significant necroinflammation was defined as a Knodell HAI of 7
or more. Significant fibrosis was defined as an Ishak score of 3 or
more, meaning the presence of bridging fibrosis or cirrhosis.
All statistical analyses were performed using SPSS version 16.0
(SPSS Inc, Chicago, Illinois). The Mann-Whitney U-test was used
for continuous variables with a skewed distribution; Pearson’s chi
squared test was used for categorical variables. Multivariate
logistic regression was used to determine whether the identified
variables associated with advanced histologic abnormalities were
independent risk factors. A two-sided p value of ,0.05 was
considered statistically significant.
Results
The baseline characteristics of the study population are depicted
in Table 2. Two hundred and eleven patients were HBeAg-
positive, of which 40 , 78 and 93 patients had a normal ALT, ALT
1–26ULN and ALT more than 26ULN respectively. Of the 108
HBeAg-negative patients, only four (3.7%) had normal ALT
levels.
The distribution of liver necroinflammation and fibrosis is
shown in Figures 1 and 2. Significant necroinflammation and
fibrosis were found in 54.2% (57.8% for HBeAg-positive, 47.2%
for HBeAg-negative) and 27.6% (24.6% for HBeAg-positive,
33.3% for HBeAg-negative) of patients respectively. Altogether 88
patients had significant fibrosis, of which 32 (36.4%) had an ALT
level of 1 to 26ULN. Six patients (5 HBeAg-positive, 1 HBeAg-
negative) had histologic evidence of cirrhosis. The distribution of
significant liver fibrosis among different age groups is shown in
Figure 3. For the whole study population, the proportion of
significant fibrosis increased from 18.3% in patients with an age of
Table 1. Inclusion criteria concerning ALT and HBV DNA for
all 319 patients.
HBeAg-positive 88 patients ALT,106ULN
HBV DNA$1.4610
6 copies/mL
53 patients ALT 1.3–106ULN
HBV DNA$1610
5 copies/mL
49 patients ALT 1.3 – 106ULN
HBV DNA$1610
6 copies/mL
15 patients ALT 1.3 – 106ULN
HBV DNA$3610
6 copies/mL
6 patients ALT , 106ULN
HBV DNA$1610
6 copies/mL
HBeAg-negative 63 patients ALT 1.3–106ULN
HBV DNA$1610
4 copies/mL
24 patients ALT 1.3–106ULN
HBV DNA$3610
6 copies/mL
21 patients ALT 1.3–106ULN
HBV DNA$1610
6 copies/mL
ULN=upper limit of normal.
doi:10.1371/journal.pone.0032622.t001
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positive patients show an increasing prevalence of significant
fibrosis with age (p=0.001). A similar trend was seen in HBeAg-
negative patients, except for the group of age less than 30 years
(n=14).
Patients were further analyzed according to different stages of
disease. Among the 40 HBeAg-positive patients with a normal
serum ALT, 9 (22.5%) had significant necroinflammation and of
these 9 patients, 2 (22.2%) had significant fibrosis. These 9 patients
had a median age of 29 (range: 17 to 42) and a median ALT of 26
(range: 18 to 53). However, only 17 patients (42.5%) had an ALT
level within the normal reference ranges suggested by Prati et al
[17] (i.e. 30 U/L for men and 19 U/L for women). Among these
17 patients, only 2 (11.8%) showed significant necroinflammation
and none had significant fibrosis. A comparison of fibrosis scores
between those with ALT levels within the Prati criteria and those
exceeding the Prati criteria among all 40 patients is shown in
Figure 4. Patients with ALT levels exceeding the Prati criteria
were more likely to have significant fibrosis (p=0.024).
One hundred and seventy-one HBeAg-positive patients had an
elevated ALT. Univariate analysis of showed that age (p=0.015),
albumin (p=,0.001), ALT (p=0.01), AST (p=0.005) and
platelet count (p=0.012) were associated with significant necroin-
flammation, while age (p,0.001), ALT (p=0.013), AST
(p,0.001) and platelet count (p=0.005) were also associated with
significant fibrosis. The multivariate analysis of clinical parameters
independently associated with significant necroinflammation or
fibrosis is shown in Table 3. A lower serum albumin (p=0.001)
and platelet count (p=0.037) were independently associated with
significant necroinflammation, while older age, higher AST and
lower platelet count were independently associated with significant
fibrosis (p=0.007, 0.047 and 0.045 respectively). A higher ALT
was not independently associated with significant fibrosis
(p=0.345). The Ishak fibrosis scores among the 78 patients with
an ALT level of 1–26ULN were compared with the 93 patients
with an ALT of more than 26ULN (Figure 5). There was no
significant difference noted (p=0.098). After revising the ULN of
ALT according to the Prati criteria, the fibrosis scores of patients
with ALT 1–26ULN (n=33) were compared with patients having
Table 2. Baseline Characteristics of all 319 patients.
Patient Characteristic HBeAg-positive HBeAg-positive HBeAg-negative
Normal ALT Elevated ALT (n=108)
(n=40) (n=171)
Age 32 (17–43) 32 (16–60) 46 (18–63)
Male 62.5% (n=25) 67.3% (n=115) 71.3% (n=77)
Albumin (g/L) 47 (43–52) 45 (29–55) 46 (40–53)
Bilirubin (umol/L) 9 (5–22) 11 (3–31) 13 (3–28)
ALT (U/L) 27 (14–55) 93 (38–636) 90 (41–576)
#16ULN 100% (n=40) - 3.7% (n=4)
1–26ULN - 45.6% (n=78) 48.1% (n=52)
.26ULN - 54.4% (n=93) 48.1% (n=52)
AST (U/L) 23 (15–39) 56 (23–304) 55 (26–255)
Platelet (610
9/L) 211 (148–308) 166 (89–334) 189 (80–331)
HBV DNA (log IU/mL) 8.14 (4.83–10.96) 7.89 (3.48–14.00) 5.71 (2.67–9.42)
Continous variables expressed in median (range).
ULN=Upper limit of normal.
doi:10.1371/journal.pone.0032622.t002
Figure 1. Distribution of liver necroinflammation (graded by
Knodell histologic activity index) among 319 chronic hepatitis
B patients.
doi:10.1371/journal.pone.0032622.g001
Figure 2. Distribution of liver fibrosis (staged by Ishak fibrosis
score) in 319 chronic hepatitis B patients.
doi:10.1371/journal.pone.0032622.g002
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difference (p=0.106).
From the univariate analysis of 108 HBeAg-negative patients,
albumin (p,0.001), ALT (p=0.038), AST (p=0.013) and HBV
DNA (p=0.001) were associated with significant necroinflamma-
tion, while only platelet count (p=0.005) and HBV DNA
(p=0.002) were associated with significant fibrosis. The multivar-
iate analysis of clinical parameters independently associated with
significant necroinflammation and fibrosis in HBeAg-negative
disease are shown in Table 3. A lower serum albumin (p=0.003)
and a higher serum HBV DNA level (p=0.004) were indepen-
dently associated with significant necroinflammation, while a low
platelet count (p=0.015) and an increased HBV DNA level
(p=0.020) were independently associated with significant fibrosis.
Increasing age and elevated ALT levels were not independently
associated with significant fibrosis (p=0.779 and 0.544 respecti-
vely).The Ishak fibrosis scores among patients with an ALT level of
1–26ULN (n=52) were compared with those having an ALT
level of more than 26ULN (n=52) (Figure 5). There was again no
significant difference (p=0.838). After the Prati criteria revision,
Figure 3. Distribution of significant liver fibrosis (Ishak fibrosis score $3) among different age groups.
doi:10.1371/journal.pone.0032622.g003
Figure 4. Comparison of Ishak fibrosis scores among HBeAg-positive patients with normal ALT (p=0.024).
doi:10.1371/journal.pone.0032622.g004
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than 26ULN respectively, fibrosis score also had no significant
difference (p=0.485).
Discussion
Various treatment guidelines require a certain ALT threshold
for treatment decisions. Both the guidelines from the American
Association for the Study of Liver Diseases (AASLD) [12] and the
Asia-Pacific Association for the Study of the Liver (APASL) [13]
only consider treatment when ALT is more than 26ULN, while
treatment is optional for ALT 1 to 2 times6ULN with liver biopsy
recommended. Using such an ALT threshold is open to debate,
especially when previous studies had shown CHB patients with a
normal ALT at the upper range had an increased risk of long-term
cirrhotic complications and HCC [25,26]. Our present study
investigated the association of various routinely available clinical
parameters, including ALT, with liver histology for all three phases
of disease in CHB: the immune tolerant phase, the immune
clearance phase and HBeAg-negative disease.
In the present study, we first examined the role of normal ALT
levels in predicting liver histology. 22.5% (9 out of 40) of HBeAg-
positive patients with a normal ALT had significant histologic
abnormalities present. A significant proportion of these patients had
abnormal ALT levels using the reference ranges suggested by Prati
et al [17]. Therefore, the findings of our study support lowering the
currently accepted reference ranges for ALT. In fact, an Asian study
based on 1105 healthy individuals also concluded the ULN of ALT
should be lowered, this time to 33 U/L for men and 25 U/L for
women [27]. In addition, patients with an ALT above 0.56ULN
(defined as 53 U/L for male and 36 U/L for female in that study)
werealready showntoat anincreasedrisk ofcirrhotic complications
[25]. Thus, HBeAg-positive patients with a serum ALTat the upper
range of the traditionally-accepted normal ranges may in fact be in
the immune clearance phase, and hence leading to significant
fibrosis on liver histology. A previous study found 39% of HBeAg-
positive patients witha normal ALT to havesignificant fibrosis [16].
Further population studies in different ethnic groups are needed to
define the exact suitable reference ranges for ALT.
We then continued to investigate whether there was any
difference in liver histology in patients with different levels of
elevated ALT. Several studies had demonstrated that there was no
good association between ALT levels and fibrosis [16,21,28]. Our
current study also found that the degree of ALT elevation was not
Table 3. Clinical parameters predictive of significant liver necroinflammation and fibrosis by multivariate analysis.
Clinical Parameter p value Odds ratio 95% Confidence Interval
HBeAg-positive with
elevated ALT (n=171)
Knodell HAI $7 (n=113) Albumin (g/L) 0.001 0.828 0.738–0.929
Platelet (610
9/L) 0.037 0.993 0.986–1.000
Ishak Fibrosis score $3 (n=50) Age (years) 0.007 1.048 1.013–1.084
AST (U/L) 0.047 1.108 1.000–1.036
Platelet (610
9/L) 0.045 0.992 0.985–1.000
HBeAg-negative (n=108) Knodell HAI $7 (n=51) Albumin (g/L) 0.003 0.792 0.680–0.923
DNA (log IU/mL) 0.004 1.741 1.194–2.540
Ishak Fibrosis score $3 (n=36) Platelet (610
9/L) 0.015 0.988 0.978–0.998
DNA (log IU/mL) 0.020 1.513 1.066–2.147
doi:10.1371/journal.pone.0032622.t003
Figure 5. Comparison of Ishak fibrosis scores between ALT 1–26ULN and ALT .26ULN in both HBeAg-positive and HBeAg-
negative patients.
doi:10.1371/journal.pone.0032622.g005
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fibrosis for both HBeAg-positive and -negative patients. In
addition, there was no significance difference in fibrosis staging
for both groups of patients with an ALT level of 1–26ULN and
more than 26ULN (p=0.098 and p=0.838 respectively).
Therefore, using the ALT threshold of more than 26ULN in
selecting patients for treatment has the potential of not treating
patients with significant fibrosis or cirrhosis. However, this finding
should be further confirmed by studies with larger number of
HBeAg-positive and -negative patients with different ALT levels.
Increasing age was independently associated with significant
fibrosis in HBeAg-positive patients with an elevated ALT, which is
consistent with previous studies [16,19,29]. In our present study,
age had no association with fibrosis in HBeAg-negative disease,
with a substantial proportion of young patients of age 30 or less
having significant fibrosis (35.7%, 5 out of 14). While this could be
related to the small sample size for these patients, another possible
explanation is that the majority of HBeAg-negative patients in our
study (96.3%, 105 out of 108) had an elevated ALT (median level
90 U/L) and HBV DNA (median level 5.71 log IU/mL). This
may represent a special group of patients who underwent HBeAg
seroconversion at a relatively younger age (median age of HBeAg
seroconversion in our locality is 35 years [25]) and yet having a
more serious disease as reflected by high ALT and HBV DNA
levels. Regardless of this, a study in Asia had shown the prevalence
of significant fibrosis among HBeAg-negative patients with the age
of less than 25 years to be 17% [29], which is much higher than
figures reported in Europe [20]. This can be explained by Asian
patients acquiring the infection perinatally, with liver injury
starting early in life.
For HBeAg-negative disease, increased HBV DNA levels were
independently associated with significant fibrosis. The findings are
in line with the suggestion of suppressing HBV DNA permanently
as a treatment end point [30], especially when long-term viral
suppression has been shown to reverse histologic damage [31,32].
Serum HBV DNA levels had no association with fibrosis in the
immune clearance phase, which can be explained by an extensive
immune-mediated response leading to low viremic levels despite
significant abnormalities on histology [33]. Although a study from
Taiwan showed that normal ALT levels in HBeAg-negative
disease are associated with a good prognosis and recommended
treatment initiation only for patients with ALT levels more than
26ULN [14], HBV DNA measurements were not incorporated in
that study. A large population study has shown elevated HBV
DNA levels in noncirrhotic HBeAg-negative patients with normal
ALT to be associated with an increased risk of HCC [7].
Among HBeAg-positive patients with elevated ALT (n=171),
both elevated AST and low platelet count were independently
associated with significant fibrosis, although the p values were only
borderline significant (p=0.047 and 0.045 respectively). These
findings are however consistent with a previous study showing that
both AST and platelet count are associated with significant
fibrosis, from which the AST to platelet ratio index (APRI) was
derived [34]._In addition, our current findings are also in line with
our previous study in which AST and platelet count were used to
create a model to predict significant fibrosis [22]. Another model
known as the APGA (AST/platelet/GGT/AFP) score showed
promising results when correlating with liver stiffness measured by
transient elastography in CHB. Further studies correlating with
actual histologic specimens would be needed to determine its
clinical applicability [35].
There are several limitations in our study, including its
retrospective nature, the different biopsy methods used and the
lack of HBeAg-negative patients with normal ALT. Although the
differences in inclusion criteria would result in selection bias, our
present study was able to recruit patients from different phases of
disease, thus making the study more representative of the whole
CHB patient population. HBV genotype and the presence of the
core-promoter mutation were not checked in our present study,
which could be important since previous small-scale studies found
genotype C and the core-promoter mutation to be associated with
significant histologic abnormalities [19,36]. However, the deter-
mination of HBV genotype and core promoter mutations requires
more advanced molecular diagnostics, and may not be available
for routine clinical practice. Since serum ALT and HBV DNA
levels tend to fluctuate with time [37], the measurement of each
clinical parameter at several time points might be more
representative. An average ALT obtained by integral calculus
would be one such method [38]. However, whether an average
value or a single value at the time of biopsy would have better
histologic correlation and prognostic determination in a cross-
sectional study would require further evaluation. Our study also
lacked clinical information concerning the patient’s metabolic
profile i.e. the presence of diabetes mellitus or insulin resistance.
Nevertheless, recent studies focusing on Chinese CHB patients did
not show any association between metabolic factors and liver
disease severity [39,40].
In conclusion, ALT is not a useful marker for the decision of
commencing antiviral therapy in CHB because of its poor
correlation with significant liver injury in both HBeAg-positive
and -negative patients. Patients with ALT levels less than 26ULN
should be considered for possible treatment if histology, or other
non-invasive assessment such as transient elastography, shows
significant fibrosis. HBeAg-positive CHB with a normal ALT
might already have significant histologic abnormalities, which
supports the lowering of the current ALT reference ranges.
Increased HBV DNA levels and low platelet count are associated
with significant fibrosis in HBeAg-negative disease.
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